title: Valbenazine for the treatment of tardive dyskinesia.
abstract: Valbenazine (NBI-98854, Ingrezza) is a highly selective vesicular monoamine transporter 2 (VMAT2) inhibitor that modulates dopamine release during nerve communication. The pharmacological target VMAT2 may play an important role in the treatment of tardive dyskinesia (TD), an iatrogenic condition associated with the administration of antipsychotic medication for long periods and characterized by rapid, repetitive, stereotypic, involuntary movements of the face and extremities. There are currently no Food and Drug Administration (FDA)-approved drugs for the treatment of TD. Results of clinical trials have shown a distinctive improvement in TD symptoms during valbenazine administration and a new drug application submitted to the FDA in August 2016 is undergoing priority review with a decision expected in April 2017.
authors.affiliation: Freelance Medical Writer, Ely, UK. nuriabarquero@hotmail.com.
authors.forename: N
authors.initials: N
authors.lastname: Barquero
mesh_terms: D000818:Animals; D004298:Dopamine / Q000378:metabolism; D006801:Humans; D000071057:Tardive Dyskinesia / Q000188:drug therapy* / Q000503:physiopathology; D013747:Tetrabenazine / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D014633:Valine / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D050493:Vesicular Monoamine Transport Proteins / Q000037:antagonists & inhibitors* / Q000378:metabolism
chemical_list: C493452:SLC18A2 protein, human; D050493:Vesicular Monoamine Transport Proteins; C000603978:valbenazine; D014633:Valine; D004298:Dopamine; D013747:Tetrabenazine
keywords: Ingrezza; NBI-98854; Tardive dyskinesia; Valbenazine